Literature DB >> 33096377

A redox-triggered C-centered free radicals nanogenerator for self-enhanced magnetic resonance imaging and chemodynamic therapy.

Jian Chen1, Xiaobo Wang2, Ying Zhang1, Shouren Zhang1, Huili Liu1, Jinxiang Zhang3, Han Feng4, Bo Li4, Xinyu Wu4, Yongju Gao5, Baocheng Yang6.   

Abstract

Current chemodynamic therapy (CDT) has been restricted by the requirement of strongly acidic conditions, insufficient endogenous H2O2 and upregulated cellular antioxidant defense. To overcome these obstacles, the carrier-free Fe(III)-ART nanoparticle is developed via coordination driven self-assembly of Fe3+ and hydrolyzed ART and evaluated as a redox-triggered C-centered free radicals nanogenerator for self-enhanced magnetic resonance imaging and chemodynamic therapy. The carrier-free Fe(III)-ART NPs can be triggered by intracellular GSH to release ART and Fe3+, which is further reduced to Fe2+ that catalyzed the endoperoxide of ART to generate C-centered free radicals. Notably, unlike current CDT, such a free radical generation process is without reliance on pH or endogenous H2O2. Meanwhile, the concurrent GSH depletion can diminish the antioxidation of tumors and enhance CDT. The C-centered free radicals-mediated apoptosis and GSH depletion-induced ferrotosis act in synergy, leading to potent tumor growth inhibition and superior anticancer efficacy in vitro and in vivo. Moreover, Fe(III)-ART NPs exhibit redox-triggered T2 relaxivity and contribute to activatable MRI-guided CDT. The development of biodegradable Fe(III)-ART NPs with superior anticancer efficacy, favorable pharmacokinetics and good biocompatibility provides a promising strategy to break through the bottlenecks of traditional CDT and greatly promotes the development of next-generation cancer theranostics.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artemisinin; C-centered free radicals; Fenton reaction; Ferroptosis; Glutathione

Year:  2020        PMID: 33096377     DOI: 10.1016/j.biomaterials.2020.120457

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Assembling p53 Activating Peptide With CeO2 Nanoparticle to Construct a Metallo-Organic Supermolecule Toward the Synergistic Ferroptosis of Tumor.

Authors:  Jingmei Wang; Wenguang Yang; Xinyuan He; Zhang Zhang; Xiaoqiang Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28

Review 2.  Research Progress on Improving the Efficiency of CDT by Exacerbating Tumor Acidification.

Authors:  Wenting Chen; Jinxi Liu; Caiyun Zheng; Que Bai; Qian Gao; Yanni Zhang; Kai Dong; Tingli Lu
Journal:  Int J Nanomedicine       Date:  2022-06-10

Review 3.  The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer.

Authors:  Yingying Hu; Nan Guo; Ting Yang; Jianghong Yan; Wenjun Wang; Xiang Li
Journal:  Oxid Med Cell Longev       Date:  2022-01-04       Impact factor: 6.543

Review 4.  Targeting ferroptosis-based cancer therapy using nanomaterials: strategies and applications.

Authors:  Lianxiang Luo; Han Wang; Wen Tian; Xiaoling Li; Zheng Zhu; Riming Huang; Hui Luo
Journal:  Theranostics       Date:  2021-10-22       Impact factor: 11.556

5.  Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.

Authors:  Qiao-Mei Zhou; Yuan-Fei Lu; Jia-Ping Zhou; Xiao-Yan Yang; Xiao-Jie Wang; Jie-Ni Yu; Yong-Zhong Du; Ri-Sheng Yu
Journal:  J Nanobiotechnology       Date:  2021-11-08       Impact factor: 10.435

Review 6.  Chemodynamic nanomaterials for cancer theranostics.

Authors:  Jingqi Xin; Caiting Deng; Omer Aras; Mengjiao Zhou; Chunsheng Wu; Feifei An
Journal:  J Nanobiotechnology       Date:  2021-06-28       Impact factor: 10.435

Review 7.  Metal-Coordinated Supramolecular Self-Assemblies for Cancer Theranostics.

Authors:  Jiating Xu; Jun Wang; Jin Ye; Jiao Jiao; Zhiguo Liu; Chunjian Zhao; Bin Li; Yujie Fu
Journal:  Adv Sci (Weinh)       Date:  2021-06-18       Impact factor: 16.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.